<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03490604</url>
  </required_header>
  <id_info>
    <org_study_id>DROUILLARD AOI 2017</org_study_id>
    <nct_id>NCT03490604</nct_id>
  </id_info>
  <brief_title>Ambulatory Measurement of Physical Activity in Pancreatic Cancer Patients</brief_title>
  <acronym>ARABICA</acronym>
  <official_title>Ambulatory Measurement of Physical Activity in Pancreatic Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pancreatic cancer is the 5th leading cause of death from cancer in France. When chemotherapy&#xD;
      can be proposed, the choice of treatment is currently based on the patient's profile and&#xD;
      expected tolerance. The endpoints currently used in trials, such as time to therapeutic&#xD;
      failure, do not take into account the patient's experience of the disease. The use of quality&#xD;
      of life questionnaires is often proposed, but frequent missing data and filling time can be a&#xD;
      problem. In oncology, some studies have demonstrated, through questionnaires, the link&#xD;
      between physical activity and quality of life. In this situation, ambulatory measurement of&#xD;
      physical activity by wrist actimetry could be an integrative reflection of the impact of the&#xD;
      disease and treatment (efficacy, tolerance) on patients. This type of evaluation, if accepted&#xD;
      by patients, could usefully complement the measurement of quality of life in this population.&#xD;
      No study has specifically looked at the use of devices of this type in the context of&#xD;
      digestive cancer. The investigators propose to evaluate the acceptance of this type of device&#xD;
      by pancreatic cancer patients receiving chemotherapy before evaluating its potential&#xD;
      interest.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2, 2018</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>average time wearing the accelerometer, in hours</measure>
    <time_frame>every 2 weeks for 6 months</time_frame>
    <description>the amount of time the accelerometer is not worn will be estimated using the standard deviation and range of acceleration in each of the 3 axes, calculated for consecutive 15-minute windows</description>
  </primary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Unresectable Pancreatic Adenocarcinoma</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>wrist-worn accelerometer</intervention_name>
    <description>accelerometer worn on the patient's wrist, changed every 15 Â± 7 days for 6 months when the patient comes for a chemotherapy session</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Auto-questionnaires</intervention_name>
    <description>Questionnaire regarding physical activity over the previous 7 days, questionnaires EORTC QLQ-C30 and EORTC QLQ-PAN26</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients followed in the hospital unit&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with unresectable pancreatic adenocarcinoma for whom an indication for&#xD;
             chemotherapy has been decided upon after a multidisciplinary consultation meeting;&#xD;
&#xD;
          -  Adult patient;&#xD;
&#xD;
          -  Patients able to understand spoken and written French,&#xD;
&#xD;
          -  Patient has given consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  WHO ECOG stage III or IV ;&#xD;
&#xD;
          -  Patient suffering from a major physical disability (hemiplegia, paraplegia, myopathy,&#xD;
             amputation of a limb);&#xD;
&#xD;
          -  Any alteration of comprehension capacities making self-evaluation impossible;&#xD;
&#xD;
          -  Protected adult;&#xD;
&#xD;
          -  Patient not affiliated to a national health insurance scheme;&#xD;
&#xD;
          -  Pregnant or nursing women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chu Dijon Bourogne</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine DROUILLARD</last_name>
      <phone>03.80.29.37.50</phone>
      <email>antoine.drouillard@chu-dijon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 30, 2018</study_first_submitted>
  <study_first_submitted_qc>March 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2018</study_first_posted>
  <last_update_submitted>February 24, 2021</last_update_submitted>
  <last_update_submitted_qc>February 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

